NaQuinate : Haoma Medica completes human trial of osteoporosis candidate
Haoma Medica has wrapped up a first-in-human trial for NaQuinate, a naphthoquinone carboxylic acid, which is being developed as an oral treatment for osteoporosis. The UK-based biotech company initiated the human trial of NaQuinate last year in healthy adults for assessing its single and multiple doses. The primary goal of the trial was to evaluate […]